| Symptoms and functional impairment assessed 8 months after mild COVID-19 among health care workers S Havervall, A Rosell, M Phillipson, SM Mangsbo, P Nilsson, S Hober, ... Jama 325 (19), 2015-2016, 2021 | 414 | 2021 |
| Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy SM Mangsbo, LC Sandin, K Anger, AJ Korman, A Loskog, TH Tötterman Journal of immunotherapy 33 (3), 225-235, 2010 | 245 | 2010 |
| Tumor-specific bacteriophages induce tumor destruction through activation of tumor-associated macrophages F Eriksson, P Tsagozis, K Lundberg, R Parsa, SM Mangsbo, ... The Journal of Immunology 182 (5), 3105-3111, 2009 | 141 | 2009 |
| AdCD40L Immunogene Therapy for Bladder Carcinoma—The First Phase I/IIa Trial PU Malmström, ASI Loskog, CA Lindqvist, SM Mangsbo, M Fransson, ... Clinical Cancer Research 16 (12), 3279-3287, 2010 | 131 | 2010 |
| The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell–dependent tumor immunity SM Mangsbo, S Broos, E Fletcher, N Veitonmäki, C Furebring, E Dahlén, ... Clinical Cancer Research 21 (5), 1115-1126, 2015 | 106 | 2015 |
| Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic … A Nasi, S McArdle, G Gaudernack, G Westman, C Melief, J Rockberg, ... Toxicology reports 7, 768-771, 2020 | 105 | 2020 |
| Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer LC Sandin, A Orlova, E Gustafsson, P Ellmark, V Tolmachev, ... Cancer immunology research 2 (1), 80-90, 2014 | 101* | 2014 |
| The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses L Christiansson, S Söderlund, S Mangsbo, H Hjorth-Hansen, M Höglund, ... Molecular cancer therapeutics 14 (5), 1181-1191, 2015 | 90 | 2015 |
| Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo LC Sandin, F Eriksson, P Ellmark, ASI Loskog, TH Tötterman, ... Oncoimmunology 3 (1), e27614, 2014 | 87 | 2014 |
| Cancer vaccines: Adjuvant potency, importance of age, lifestyle, and treatments S Cuzzubbo, S Mangsbo, D Nagarajan, K Habra, AG Pockley, ... Frontiers in immunology 11, 615240, 2021 | 83 | 2021 |
| Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma L van Hooren, A Vaccaro, M Ramachandran, K Vazaios, S Libard, ... Nature Communications 12 (1), 4127, 2021 | 76 | 2021 |
| Fcγ receptor IIb strongly regulates Fcγ receptor-facilitated T cell activation by dendritic cells N van Montfoort, PAC t Hoen, SM Mangsbo, MGM Camps, P Boross, ... The Journal of Immunology 189 (1), 92-101, 2012 | 76 | 2012 |
| Local checkpoint inhibition of CTLA‐4 as a monotherapy or in combination with anti‐PD1 prevents the growth of murine bladder cancer L van Hooren, LC Sandin, I Moskalev, P Ellmark, A Dimberg, P Black, ... European journal of immunology 47 (2), 385-393, 2017 | 75 | 2017 |
| Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment E Eriksson, R Moreno, I Milenova, L Liljenfeldt, LC Dieterich, ... Gene therapy 24 (2), 92-103, 2017 | 71 | 2017 |
| CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity SM Mangsbo, C Ninalga, M Essand, A Loskog, TH Tötterman Journal of immunotherapy 31 (1), 34-42, 2008 | 66 | 2008 |
| Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID‐19 S Havervall, H Ng, A Jernbom Falk, N Greilert‐Norin, A Månberg, ... Journal of internal medicine 291 (1), 72-80, 2022 | 59 | 2022 |
| Both CD4+ FoxP3+ and CD4+ FoxP3− T cells from patients with B‐cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro CA Lindqvist, LH Christiansson, I Thörn, S Mangsbo, G Paul‐Wetterberg, ... Immunology 133 (3), 296-306, 2011 | 54 | 2011 |
| Complement activation by CpG in a human whole blood loop system: mechanisms and immunomodulatory effects SM Mangsbo, J Sanchez, K Anger, JD Lambris, KN Ekdahl, AS Loskog, ... The Journal of Immunology 183 (10), 6724-6732, 2009 | 52 | 2009 |
| Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients A Loskog, A Maleka, S Mangsbo, E Svensson, C Lundberg, A Nilsson, ... British journal of cancer 114 (8), 872-880, 2016 | 48 | 2016 |
| Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients A Schiza, J Wenthe, S Mangsbo, E Eriksson, A Nilsson, TH Tötterman, ... Journal of translational medicine 15, 1-11, 2017 | 47 | 2017 |
Luuk van Hooren在 sanofi.com 的电子邮件经过验证
